Recently Featured

Novo’s Parkinson’s Cell Therapy Finds New Home; GSK Partners for Drug Sales in China

May 15, 2026
Novo Nordisk has successfully secured a partnership for its early-stage Parkinson’s cell therapy, marking a significant advance in the treatment landscape for this neurodegenerative condition. This development comes at a time when the demand for innovative therapies in neurology is surging, driven by an aging population and increasing prevalence of Parkinson’s disease. The collaboration is…

RegVelo AI Model Predicts Cell Fate, Tackles Developmental Disorders and Cancer

May 15, 2026
In a new study published in Cell, researchers from Stowers Institute of Medical Research have developed an AI model named RegVelo that bridges two critical aspects of single-cell biology: estimating cellular changes over time and inferring the gene regulatory networks that govern these transformations. This innovative approach could significantly enhance the development of cell therapies…

Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial

May 14, 2026
Inhibrx has unveiled promising data suggesting that its investigational cancer drug may enhance the efficacy of Merck’s Keytruda, a breakthrough immunotherapy. This development comes at a critical time for Inhibrx, which has recently been the focus of buyout speculation, potentially positioning the company as an attractive acquisition target for larger pharmaceutical entities seeking to bolster…

MHRA opens UK-wide consultation on redefining gene therapies

May 14, 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) has initiated a UK-wide consultation aimed at redefining the regulatory framework surrounding gene therapies. This move is designed to align regulations with the rapid advancements in scientific research and technological innovations within the field. The consultation seeks to gather insights from industry stakeholders, including regulatory professionals, quality…

Ongoing Cases